Food and Drug
Administration
Psychopharmacologic Drugs Advisory Committee
March 23, 2006
Briefing Information
Cephalon, Inc.
Disclaimer
The statements contained in this document(s) are those of the product's
sponsor, not FDA, and FDA does not necessarily agree with
the sponsor's statements. FDA has not made a final determination
about the safety or effectiveness of the product described
in this document.
Modafinil (CEP-1538) Tablets
FDA
Disclaimer
Portions of this document have been determined
to be exempt from disclosure under the Freedom of Information
Act (the FOIA) (5 U.S.C. §552).
These redacted portions
will appear as white space on the screen or on the printed
page.
Briefing Information
FDA
FDA Table of Contents